Kapspargo Sprinkle Available to Treat Hypertension, Angina, Heart Failure

This article originally appeared here.
Share this content:
Kapspargo Sprinkle is the first extended-release sprinkle formulation of metoprolol succinate.
Kapspargo Sprinkle is the first extended-release sprinkle formulation of metoprolol succinate.

Sun Pharma announced the availability of Kapspargo Sprinkle (metoprolol succinate extended-release) for the treatment of hypertension in patients aged ≥6 years; for long-term treatment of angina pectoris, to reduce angina attacks and to improve exercise tolerance; and to reduce the risk of cardiovascular mortality and heart failure hospitalization in patients with heart failure.

Kapspargo Sprinkle is the first extended-release sprinkle formulation of metoprolol succinate, a beta1-selective (cardioselective) adrenoreceptor blocking agent. For patients unable to swallow an intact capsule, the pellets can be sprinkled over soft food (eg, applesauce, yogurt, pudding) or given via a nasogastric (NG) tube. Each pellet serves as a separate drug delivery unit that provides metoprolol continuously over the dosage interval. 

Kapspargo Sprinkle is available as 25mg, 50mg, 100mg, and 200mg strength capsules in 30-count bottles. For patients taking metoprolol succinate extended-release tablets at a dose of 25mg to 200mg daily, Kapspargo Sprinkle may be substituted for the tablets using the same total daily dose of metoprolol succinate.

For more information call (800) 406-7984 or visit SunPharma.com.

You must be a registered member of The Cardiology Advisor to post a comment.

Sign Up for Free e-Newsletters